Checkpoint Therapeutics, Inc. Stock News

The stock price of Checkpoint Therapeutics Inc (NASDAQ: CKPT) increased by over 13% during intraday trading. This is why it happened.

Based on its latest clinical trial data, this small-cap biotech could have a best-in-class treatment for advanced skin cancer on the way.

During the last session, Checkpoint Therapeutics Inc. (NASDAQ:CKPT)s traded shares were 0.96 million, with the beta value of the company hitting 1.62. At the end of the trading day, the stocks price was $2.94, reflecting an intraday gain of 2.80% or $0.08. The 52-week high for the CKPT share is $5.38, that puts it down Will Checkpoint Therapeutics Inc. (NASDAQ: CKPT) Stock Boom Or Bust From Here? Read More »

In the last trading session, 1.33 million shares of the Checkpoint Therapeutics Inc. (NASDAQ:CKPT) were traded, and its beta was 1.62. Most recently the companys share price was $2.80, and it changed around -$0.17 or -5.72% from the last close, which brings the market valuation of the company to $236.94M. CKPT currently trades at a An Analysis Of Checkpoint Therapeutics Inc. (NASDAQ: CKPT), And Its Business Forecast Read More »

Checkpoint Therapeutics, Inc. (NASDAQ:CKPT) was the target of unusually large options trading on Thursday. Stock traders bought 7,123 put options on the stock. This represents an increase of 609% compared to the average daily volume of 1,005 put options. CKPT opened at $2.95 on Friday. Checkpoint Therapeutics has a 52 week low of $2.20 and [] The post Investors Buy High Volume of Checkpoint Therapeutics Put Options (NASDAQ:CKPT) appeared first on ETF Daily News .

Checkpoint Therapeutics Inc. (NASDAQ:CKPT)s traded shares stood at 1.13 million during the last session, with the companys beta value hitting 1.62. At the close of trading, the stocks price was $3.08, to imply an increase of 5.48% or $0.16 in intraday trading. The CKPT shares 52-week high remains $5.38, putting it -74.68% down since that Checkpoint Therapeutics Inc. (NASDAQ: CKPT) Has Fallen -74.68% From Its Highs, What Comes Next? Read More »

WALTHAM, Mass., Dec. 08, 2021 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (Checkpoint) (NASDAQ: CKPT), a clinical-stage immunotherapy and targeted oncology company, today announced the initiation of the CONTERNO study, a global, randomized Phase 3 trial of cosibelimab in combination with pemetrexed and platinum chemotherapy for the first-line treatment of patients with non-squamous non-small cell lung cancer (NSCLC). The primary endpoint for the CONTERNO Phase 3 trial is overall survival (OS), and the study is designed to support full regulatory approvals worldwide.

Checkpoint Therapeutics expects to report top-line results before year-end, which could determine if Cosibelimab is ready for regulatory submission that could lead to an approval and commercial launch

Checkpoint Therapeutics, Inc. (NASDAQ:CKPT) B. Riley dropped their FY2021 EPS estimates for shares of Checkpoint Therapeutics in a report released on Wednesday, November 10th. B. Riley analyst J. Walsh now forecasts that the company will post earnings per share of ($0.52) for the year, down from their previous forecast of ($0.50). B. Riley also []

In the last trading session, 1.2 million Checkpoint Therapeutics Inc. (NASDAQ:CKPT) shares changed hands as the companys beta touched 1.59. With the companys per share price at $4.27 changed hands at -$0.01 or -0.23% during last session, the market valuation stood at $358.51M. CKPTs last price was a discount, traded about -26.0% off its 52-week Checkpoint Therapeutics Inc. (NASDAQ: CKPT): Can It Make A Huge Gain? Read More »

Checkpoint Therapeutics, Inc. (NASDAQ:CKPT) B. Riley lowered their FY2021 earnings per share estimates for shares of Checkpoint Therapeutics in a research report issued on Wednesday, November 10th. B. Riley analyst J. Walsh now forecasts that the company will earn ($0.52) per share for the year, down from their prior estimate of ($0.50). B. Riley []

WALTHAM, Mass., Sept. 09, 2021 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (“Checkpoint”) (NASDAQ: CKPT), a clinical-stage immunotherapy and targeted oncology company, today announced that J

NEW YORK, Aug. 05, 2021 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (“Checkpoint”) (NASDAQ: CKPT), a clinical-stage immunotherapy and targeted oncology company, today announced financial res

Checkpoint Therapeutics: Amassing A Position Ahead Of Cosibelimab Data